|
Delayed
Bombay S.E.
09:46:40 27/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 2,355.60 INR | +3.70% |
|
+6.02% | +27.91% |
| 09-25 | Caplin Point Laboratories Limited Approves Appointment of D Muralidharan as Whole Time Director | CI |
| 08-14 | Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026 |
Company Valuation: Caplin Point Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 51,529 | 45,291 | 100,038 | 152,221 | 114,409 | 172,661 | - |
| Change | - | -12.11% | 120.88% | 52.16% | -24.84% | 50.92% | - |
| Enterprise Value (EV) | 51,529 | 45,291 | 100,038 | 152,221 | 114,409 | 172,661 | 172,661 |
| Change | - | -12.11% | 120.88% | 52.16% | -24.84% | 50.92% | 0% |
| P/E | 17.3x | 12.1x | 22x | 28.5x | 17.9x | 23.8x | 20.5x |
| PBR | 3.47x | 2.41x | 4.32x | 5.34x | 3.19x | 3.91x | 3.53x |
| PEG | - | 0.5x | 1x | 1.6x | 0.9x | 1.7x | 1.3x |
| Capitalization / Revenue | 4.06x | 3.09x | 5.91x | 7.86x | 5.23x | 6.89x | 6.09x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 6.89x | 6.09x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 19.8x | 17.2x |
| EV / EBIT | 0x | 0x | - | 0x | 0x | 18.5x | 16.1x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 31.1x | 30.6x |
| FCF Yield | 4.77% | 1.72% | 1.73% | 1.58% | 2.4% | 3.22% | 3.27% |
| Dividend per Share 2 | 2 | 2 | 2.5 | 3 | - | 4 | 4 |
| Rate of return | 0.29% | 0.34% | 0.19% | 0.15% | - | 0.18% | 0.18% |
| EPS 2 | 39.26 | 49.18 | 59.9 | 70.25 | 84.11 | 95.6 | 110.7 |
| Distribution rate | 5.09% | 4.07% | 4.17% | 4.27% | - | 4.18% | 3.61% |
| Net sales 1 | 12,694 | 14,667 | 16,941 | 19,375 | 21,872 | 25,072 | 28,340 |
| EBITDA 1 | 3,947 | 4,411 | 5,514 | 6,469 | 7,609 | 8,700 | 10,050 |
| EBIT 1 | 3,478 | 4,520 | - | 5,810 | 8,036 | 9,321 | 10,752 |
| Net income 1 | 2,998 | 3,763 | 4,571 | 5,363 | 6,412 | 7,264 | 8,411 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 679.90 | 596.70 | 1,317.30 | 2,002.60 | 1,505.15 | 2,271.50 | 2,271.50 |
| Nbr of stocks (in thousands) | 75,789 | 75,903 | 75,942 | 76,012 | 76,012 | 76,012 | - |
| Announcement Date | 5/12/22 A | 5/27/23 A | 5/16/24 A | 5/15/25 A | 5/14/26 A | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.24x | - | - | - | 1.78B | |
| 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.33x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 28.87x | 7.04x | 18.70x | 2.12% | 400.54B | |
| Weighted average by Cap. | 35.22x | 8.29x | 20.40x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CAPLIPOINT Stock
- Valuation Caplin Point Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
